Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Long-Term Investments (2021 - 2023)

Historic Long-Term Investments for Ernexa Therapeutics (ERNA) over the last 3 years, with Q1 2023 value amounting to $8000.0.

  • Ernexa Therapeutics' Long-Term Investments fell 9792.21% to $8000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $8000.0, marking a year-over-year decrease of 9792.21%. This contributed to the annual value of $59000.0 for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q1 2023, Ernexa Therapeutics' Long-Term Investments is $8000.0, which was down 9792.21% from $59000.0 recorded in Q4 2022.
  • Ernexa Therapeutics' 5-year Long-Term Investments high stood at $1.0 million for Q3 2021, and its period low was $8000.0 during Q1 2023.
  • In the last 3 years, Ernexa Therapeutics' Long-Term Investments had a median value of $78500.0 in 2022 and averaged $268166.7.
  • Its Long-Term Investments has fluctuated over the past 5 years, first plummeted by 9320.0% in 2022, then crashed by 9792.21% in 2023.
  • Ernexa Therapeutics' Long-Term Investments (Quarter) stood at $1.0 million in 2021, then plummeted by 94.1% to $59000.0 in 2022, then tumbled by 86.44% to $8000.0 in 2023.
  • Its last three reported values are $8000.0 in Q1 2023, $59000.0 for Q4 2022, and $68000.0 during Q3 2022.